Goldline Pharmaceutical IPO GMP today is Rs 16.75. Investors can use this GMP along with price band and subscription status for a better IPO review.
Listed
SME IPO
GOLDLINE
Goldline Pharmaceutical IPO GMP, Subscription & Allotment Status Today
Goldline Pharmaceutical is a SME IPO with a price band of Rs 41.00 to Rs 43.00 that listed on 19 May 2026 at a listing gain of +38.95%. Track its full GMP history, subscription data and listing details here.
- Price Band
- ₹41.00 - ₹43.00
- Lot Size
- 3,000 Shares
- Bidding Closes
- 14 May 2026
- Listing Date
- 19 May 2026
Current GMP Status
₹16.75
+38.95% vs upper band
Est. Listing Gain
+38.95%
Last Trend
14 May 2026
Listing Price
₹59.75
Retail Entry
₹2,58,000
IPO Details
Complete IPO information
| Current GMP | ₹16.75 |
|---|---|
| Estimated Listing Gain | +38.95% |
| Price Band | ₹41.00 - ₹43.00 |
| Issue Price | Approx ₹43.00 Crores |
| Listing Price | ₹59.75 |
| Lot Size | 3,000 Shares |
| Issue Type | SME |
| Registrar | TBA |
| Exchange | NSE, BSE |
| Retail Quota | TBA |
| Overall Subscription | 100.14x |
| Listing Date | 19 May 2026 |
| Minimum Investment | ₹2,58,000 |
Head-to-head
Compare Goldline Pharmaceutical IPO with similar IPOs
Analysis
IPO Snapshot & Investor Takeaways
At the upper end of its price band, Goldline Pharmaceutical is priced at ₹43 per share. With a minimum lot size of 3,000 shares, a retail investor applying for one lot would need approximately ₹2,58,000 to participate in this SME issue.
The latest recorded Grey Market Premium for Goldline Pharmaceutical stands at ₹16.75, implying an estimated listing gain of around 38.95% over the issue price if it holds until listing. GMP reflects informal grey-market sentiment rather than a guaranteed outcome, and can change at any point until the day of listing.
As of the latest update, Goldline Pharmaceutical's IPO was subscribed 100.14x overall, with a category-wise breakdown of Retail 139.51x, QIB 1.31x.
SME IPOs list on the dedicated SME platform of BSE/NSE. They usually involve smaller issue sizes and a higher per-lot investment than Mainboard issues, with comparatively lower institutional participation.
Timeline
IPO roadmap at a glance
✓
Bidding Opens
12 May 2026
✓
Bidding Closes
14 May 2026
✓
Allotment
TBA
✓
Listing
19 May 2026
Grey Market Premium
Daily GMP status
| Date | GMP | Change | Gain |
|---|---|---|---|
| 14 May 2026 | ₹18.00 | - | 41.86% |
| 13 May 2026 | ₹18.00 | +₹1.00 | 41.86% |
| 12 May 2026 | ₹17.00 | - | 39.53% |
Swipe to see more →
Market Lot
Application size breakdown
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 Lot | 6,000 | ₹2,58,000 |
| Retail Maximum | 2 Lot | 6,000 | ₹2,58,000 |
| S-HNI Minimum | 3 Lot | 9,000 | ₹3,87,000 |
| S-HNI Maximum | 7 Lot | 21,000 | ₹9,03,000 |
| B-HNI Minimum | 8 Lot | 24,000 | ₹10,32,000 |
Swipe to see more →
Fund Utilization
Objects of the Issue & Official Documents
Analysis
Goldline Pharmaceutical IPO Details
| IPO Open Date | May 12, 2026 |
|---|---|
| IPO Close Date | May 14, 2026 |
| Face Value | ₹10 Per Equity Share |
| IPO Price Band | ₹41 to ₹43 Per Share |
| Issue Size | Approx ₹12 Crores |
| Fresh Issue | Approx ₹12 Crores |
| Issue Type | Book build Issue |
| IPO Listing | BSE SME |
Analysis
Goldline Pharmaceutical IPO Reservation
| Investor Category | Shares Offered | Shares (%) |
|---|---|---|
| Anchor Investor | 7,32,000 | 27.11% |
| QIB (Ex. Anchor) | 5,40,000 | 20.00% |
| NII | 3,90,000 | 14.44% |
| Retail | 9,00,000 | 33.33% |
Analysis
Goldline Pharmaceutical IPO Anchor Investors
| Anchor Bidding Date | May 11, 2026 |
|---|---|
| Shares Offered | 7,32,000 |
| Anchor Size | — |
| Lock-in Period (50% Shares - 30 Days) | 2026 |
| Lock-in Period (50% Shares - 90 Days) | 2026 |
Analysis
Goldline Pharmaceutical IPO Dates
| IPO Open Date | May 12, 2026 |
|---|---|
| IPO Close Date | May 14, 2026 |
| Basis of Allotment | May 15, 2026 |
| Refunds | May 18, 2026 |
| Credit to Demat Account | May 18, 2026 |
| IPO Listing Date | May 19, 2026 |
| Bidding Cut-off Time | May 14, 2026 – 5 PM |
Analysis
Goldline Pharmaceutical IPO Promoters & Holding Pattern
| Particular | Shares | % Share |
|---|---|---|
| Promoter Holding Pre Issue | 69,00,000 | 79.70% |
| Promoter Holding Post Issue | 96,00,000 | — |
| Promoters |
|---|
| Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal |
Analysis
Goldline Pharmaceutical IPO – Objects of the Issue
| Purpose | Amount (₹ Cr.) |
|---|---|
| Prepayment / Repayment of Borrowings | 8.90 |
| General Corporate Purpose | — |
Analysis
About Goldline Pharmaceutical IPO
Goldline Pharmaceuticals is one of the leading companies involved in the marketing of pharmaceutical products under the name Goldline. Its products are divided into 5 segments: 1. Goldline Pharma, which includes specialities like Physicians, Orthopedics, ENT, Chest Physicians, General and Speciality Surgery, Gastroenterology, Neurology, and Urology, 2. Goldline Cardinal, which includes specialities like Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians, 3. Goldline Ayushman, which includes Pediatricians, Child Specialists, Neonatologists, and General Practitioners, 4. Goldline InLife, which includes Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians, and 5. Goldline Wellness, which includes cancer therapy.
The company sells its products across various states, including Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar. Moreover, all the products of the firm are sold and distributed under the brand Goldline.
Analysis
Goldline Pharmaceutical IPO Company Financial Report
| Period Ended | Revenue (₹ Cr.) | Expense (₹ Cr.) | PAT (₹ Cr.) | Assets (₹ Cr.) |
|---|---|---|---|---|
| 2023 | 19.85 | 19.45 | 0.26 | 19.39 |
| 2024 | 23.57 | 21.04 | 1.81 | 22.93 |
| 2025 | 28.06 | 24.20 | 2.83 | 26.28 |
| Dec 2025 | 21.41 | 18.40 | 2.22 | 27.40 |
Analysis
Goldline Pharmaceutical IPO Valuation – FY2025
| KPI | Values |
|---|---|
| ROE | 35.84% |
| ROCE | 38.46% |
| EBITDA Margin | 20.79% |
| PAT Margin | 10.10% |
| Debt to Equity | 1.50 |
| EPS (Basic) | ₹4.10 |
| P/E Ratio | N/A |
| RoNW | 27.37% |
| NAV | ₹12.38 |
Analysis
Goldline Pharmaceutical IPO Peer Group Comparison
| Company | EPS | P/E Ratio | RoNW % | NAV | Income (₹ Cr.) |
|---|---|---|---|---|---|
| Mono Pharmacare Limited | 1.75 | 7.57 | 9.90% | 17.66 | 168.34 |
| Chandra Bhagat Pharma Limited | 1.14 | 28.94 | 2.86% | 39.72 | 86.72 |
Analysis
IPO Lead Managers aka Merchant Bankers
IPO Lead Managers aka Merchant Bankers
- Cumulative Capital Pvt. Ltd.
FAQ
Goldline Pharmaceutical IPO FAQs
Goldline Pharmaceutical IPO price band is Rs 41.00 to Rs 43.00. Check the latest issue price, lot size and GMP together before applying.
Goldline Pharmaceutical IPO open date is 12 May 2026, close date is 14 May 2026, and listing date is 19 May 2026.
Goldline Pharmaceutical IPO lot size is 3,000 shares. The minimum retail investment is Rs 2,58,000.
Goldline Pharmaceutical is classified as a SME IPO. This helps investors quickly understand the issue category and exchange segment.
Goldline Pharmaceutical IPO subscription status currently shows Retail 139.51x, QIB 1.31x, Overall 100.14x.
Community discussion
Comments
Share a useful question or insight about Goldline Pharmaceutical.
Leave a comment
Your email address will not be published. All comments and replies are reviewed before appearing.
Keep Exploring
Similar Recent IPOs
SME
R.K.Fashion Accessories
Price Band₹77.00 - ₹82.00
Current GMP₹0
Lot Size1,600 Shares
SME
Dove Soft
Price Band₹104.00 - ₹111.00
Current GMP₹0
Lot Size1,200 Shares
SME
Paramount Syntex
Price Band₹119.00 - ₹127.00
Current GMP₹0
Lot Size1,000 Shares
SME
Omara Ventures India
Price Band₹296.00 - ₹311.00
Current GMP₹0
Lot Size400 Shares
Loading comments...